Literature DB >> 23821325

Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.

Alice Dewdney1, David Cunningham, Ian Chau.   

Abstract

Rectal cancer remains a significant problem worldwide. Outcomes vary significantly according to the stage of disease and prognostic factors, including the distance of the tumor from the circumferential resection margin. Accurate staging, including high-resolution magnetic resonance imaging, allows stratification of patients into low-, moderate-, and high-risk disease; this information can be used to inform multidisciplinary team decisions regarding the role of neoadjuvant therapy. Both neoadjuvant short-course radiotherapy and long-course chemoradiation reduce the risk of local recurrence compared with surgery alone, but they have little impact on survival. Although there remains a need to reduce overtreatment of those patients at moderate risk, evaluation of intensified regimens for those with high-risk disease is still required to reduce distant failure rates and improve survival in these patients with an otherwise poor prognosis.

Entities:  

Keywords:  Chemoradiation; Magnetic resonance imaging; Neoadjuvant treatment; Rectal cancer

Mesh:

Year:  2013        PMID: 23821325      PMCID: PMC3720638          DOI: 10.1634/theoncologist.2013-0022

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  64 in total

1.  Oncological outcomes of transanal local excision for high risk T(1) rectal cancers.

Authors:  Ze-Yu Wu; Gang Zhao; Zhe Chen; Jia-Lin Du; Jin Wan; Feng Lin; Lin Peng
Journal:  World J Gastrointest Oncol       Date:  2012-04-15

2.  Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

Authors:  J V Schou; F O Larsen; L Rasch; D Linnemann; J Langhoff; E Høgdall; D L Nielsen; K Vistisen; A Fromm; B V Jensen
Journal:  Ann Oncol       Date:  2012-04-02       Impact factor: 32.976

3.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.

Authors:  Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.

Authors: 
Journal:  Radiology       Date:  2007-02-28       Impact factor: 11.105

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

8.  Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines.

Authors:  R Kikuchi; M Takano; K Takagi; N Fujimoto; R Nozaki; T Fujiyoshi; Y Uchida
Journal:  Dis Colon Rectum       Date:  1995-12       Impact factor: 4.585

9.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

Review 10.  The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.

Authors:  Marian Grade; Hendrik A Wolff; Jochen Gaedcke; B Michael Ghadimi
Journal:  Langenbecks Arch Surg       Date:  2012-03-02       Impact factor: 3.445

View more
  5 in total

Review 1.  Neoadjuvant Strategies: Locally Advanced Rectal Cancer.

Authors:  Shahab Ahmed; Cathy Eng
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms.

Authors:  Aeris Jane D Nacion; Youn Young Park; Nam Kyu Kim
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

3.  Prognostic significance of computed tomography-detected extramural vascular invasion in colon cancer.

Authors:  Xun Yao; Su-Xing Yang; Xing-He Song; Yan-Cheng Cui; Ying-Jiang Ye; Yi Wang
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

4.  Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.

Authors:  Antonio Avallone; Biagio Pecori; Franco Bianco; Luigi Aloj; Fabiana Tatangelo; Carmela Romano; Vincenza Granata; Pietro Marone; Alessandra Leone; Gerardo Botti; Antonella Petrillo; Corradina Caracò; Vincenzo R Iaffaioli; Paolo Muto; Giovanni Romano; Pasquale Comella; Alfredo Budillon; Paolo Delrio
Journal:  Oncotarget       Date:  2015-10-06

5.  MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy.

Authors:  Maria Rivero; Javier Peinado-Serrano; Sandra Muñoz-Galvan; Asuncion Espinosa-Sánchez; Elisa Suarez-Martinez; Blanca Felipe-Abrio; Maria Carmen Fernández-Fernández; Maria Jose Ortiz; Amancio Carnero
Journal:  Oncotarget       Date:  2018-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.